$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Development of Dual Drug Eluting Cardiovascular Stent with Ultrathin Flexible Poly(L-lactide-co-caprolactone) Coating

ACS biomaterials science & engineering, v.5 no.6, 2019년, pp.2899 - 2915  

Roopmani, Purandhi (Department of Cardiology , Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER) , Pondicherry −) ,  Satheesh, Santhosh (605006 , India) ,  Raj, David C. ,  Krishnan, Uma Maheswari

Abstract AI-Helper 아이콘AI-Helper

The pleiotropic effects of the atorvastatin-fenofibrate combination can be effectively harnessed for site-specific therapy to minimize stent-related complications. The present study aims to utilize the pleiotropic effects of these two drugs entrapped in a uniform and defect-free coating of poly(L-la...

Keyword

참고문헌 (69)

  1. Exp Clin Cardiol Buttar H. S. 229 10 2005 

  2. Bønaa, Kaare H., Mannsverk, Jan, Wiseth, Rune, Aaberge, Lars, Myreng, Yngvar, Nygård, Ottar, Nilsen, Dennis W., Kløw, Nils-Einar, Uchto, Michael, Trovik, Thor, Bendz, Bjørn, Stavnes, Sindre, Bjørnerheim, Reidar, Larsen, Alf-Inge, Slette, Morten, Steigen, Terje, Jakobsen, Ole J., Bleie, Øyvind, Fossum, Eigil, Hanssen, Tove A., Dahl-Eriksen, Øystein, Njølstad, Inger, Rasmussen, Knut, Wilsgaard, Tom, Nordrehaug, Jan E.. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. The New England journal of medicine, vol.375, no.13, 1242-1252.

  3. Celik, Turgay, Iyisoy, Atila, Kursaklioglu, Hurkan, Celik, Murat. The forgotten player of in-stent restenosis: Endothelial dysfunction. International journal of cardiology, vol.126, no.3, 443-444.

  4. Georgiadou, Panagiota, Voudris, Vassilis. Platelet activation and stent thrombosis. Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē, vol.58, no.1, 49-50.

  5. Warren, J., Baber, U., Mehran, R.. Antiplatelet therapy after drug-eluting stent implantation. Journal of cardiology, vol.65, no.2, 98-104.

  6. Am. Fam Physician Dehmer G. J. 1245 80 2009 

  7. Pendyala, L.K., Yin, X., Li, J., Chen, J.P., Chronos, N., Hou, D.. The First-Generation Drug-Eluting Stents and Coronary Endothelial Dysfunction. JACC. Cardiovascular interventions, vol.2, no.12, 1169-1177.

  8. Secemsky, Eric A., Yeh, Robert W., Kereiakes, Dean J., Cutlip, Donald E., Cohen, David J., Steg, P. Gabriel, Cannon, Christopher P., Apruzzese, Patricia K., D’Agostino Sr, Ralph B., Massaro, Joseph M., Mauri, Laura. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting : A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA cardiology, vol.2, no.5, 478-.

  9. Muramatsu, T., Onuma, Y., Zhang, Y.J., Bourantas, C.V., Kharlamov, A., Diletti, R., Farooq, V., Gogas, B.D., Garg, S., Garcia-Garcia, H.M., Ozaki, Y., Serruys, P.W.. Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. Revista española de cardiología, vol.66, no.6, 483-496.

  10. Harumi Higuchi dos Santos, Marilia, Sharma, Abhinav, Sun, Jie‐Lena, Pieper, Karen, McMurray, John J.V., Holman, Rury R., Lopes, Renato D.. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. Journal of the American Heart Association : cardiovascular and cerebrovascular disease, vol.6, no.1, e003892-.

  11. Huang, Y., Ng, H.C.A., Ng, X.W., Subbu, V.. Drug-eluting biostable and erodible stents. Journal of controlled release : official journal of the Controlled Release Society, vol.193, 188-201.

  12. Herrmann, R., Schmidmaier, G., Märkl, B., Resch, A., Hähnel, I., Stemberger, A., Alt, E.. Antithrombogenic Coating of Stents Using a Biodegradable Drug Delivery Technology. Thrombosis and haemostasis, vol.82, no.7, 51-57.

  13. Berg, Ryan, Aragon, Joseph, Royter, Vladimir, Shanley, John F., Cogert, Greg, Vermani, Renu, Kar, Saibal, Eigler, Neal, Litvack, Frank. Pimecrolimus and dual pimecrolimus-paclitaxel eluting stents decrease neointimal proliferation in a porcine model. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, vol.70, no.6, 871-879.

  14. Adriaenssens, T., Mehilli, J., Wessely, R., Ndrepepa, G., Seyfarth, M., Wieczorek, A., Blaich, B., Iijima, R., Pache, J., Kastrati, A., Schomig, A.. Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?. Journal of the American College of Cardiology, vol.49, no.12, 1265-1271.

  15. Thipparaboina, R., Khan, W., Domb, A.J.. Eluting combination drugs from stents. International journal of pharmaceutics, vol.454, no.1, 4-10.

  16. Ma, X., Oyamada, S., Gao, F., Wu, T., Robich, M.P., Wu, H., Wang, X., Buchholz, B., McCarthy, S., Gu, Z., Bianchi, C.F., Sellke, F.W., Laham, R.. Paclitaxel/sirolimus combination coated drug-eluting stent: In vitro and in vivo drug release studies. Journal of pharmaceutical and biomedical analysis, vol.54, no.4, 807-811.

  17. Raber, L., Serruys, P.W.. Late Vascular Response Following Drug-Eluting Stent Implantation. JACC. Cardiovascular interventions, vol.4, no.10, 1075-1078.

  18. Han, Seung Hwan, Quon, Michael J., Koh, Kwang Kon. Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators. Hypertension, vol.46, no.5, 1086-1092.

  19. Ortego, Mónica, Bustos, Carmen, Hernández-Presa, Miguel A, Tuñón, José, Dı́az, Cristina, Hernández, Gonzalo, Egido, Jesús. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis, vol.147, no.2, 253-261.

  20. Li, Jingjing, Jiang, Jixin, Yin, Hao, Wang, Lifeng, Tian, Ruijuan, Li, Haijie, Wang, Zengyong, Li, Dong, Wang, Yuebing, Gui, Yu, Walsh, Michael P., Zheng, Xi-Long. Atorvastatin Inhibits Myocardin Expression in Vascular Smooth Muscle Cells. Hypertension, vol.60, no.1, 145-153.

  21. Yin, Hao, Gui, Yu, Zheng, Xi-Long. 2-methoxyestradiol inhibits atorvastatin-induced rounding of human vascular smooth muscle cells. Journal of cellular physiology, vol.222, no.3, 556-564.

  22. Li, Min, Liu, Yinglin, Dutt, Parmesh, Fanburg, Barry L., Toksoz, Deniz. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. American journal of physiology. Lung cellular and molecular physiology, vol.293, no.2, L463-L471.

  23. Chen, Shuang, Liu, Baoqin, Kong, Dehui, Li, Si, Li, Chao, Wang, Huaqin, Sun, Yingxian. Atorvastatin Calcium Inhibits Phenotypic Modulation of PDGF-BB-Induced VSMCs via Down-Regulation the Akt Signaling Pathway. PloS one, vol.10, no.4, e0122577-.

  24. Int. J. Clin Exp Med. Li C. Y. 220824 9 2016 

  25. J. Physiol Pharmacol. Zemankova L. 403 66 2015 

  26. Xiao, Hongbing, Qin, Xiong, Ping, Ding, Zuo, Keqiang. Inhibition of Rho and Rac Geranylgeranylation by Atorvastatin Is Critical for Preservation of Endothelial Junction Integrity. PloS one, vol.8, no.3, e59233-.

  27. Llevadot, Joan, Asahara, Takayuki. Efecto de las estatinas en la inducción de angiogénesis y vasculogénesis. Revista española de cardiología : publicación oficial de la Sociedad Española de Cardiología, vol.55, no.8, 838-844.

  28. Antonopoulos, Alexios S, Margaritis, Marios, Lee, Regent, Channon, Keith, Antoniades, Charalambos. Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials. Current pharmaceutical design, vol.18, no.11, 1519-1530.

  29. Feng, B., Xu, L., Wang, H., Yan, X., Xue, J., Liu, F., Hu, J.F.. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochimica et biophysica acta. Molecular basis of disease, vol.1812, no.9, 1130-1137.

  30. Noonan, Jonathan E., Jenkins, Alicia J., Ma, Jian-Xing, Keech, Anthony C., Wang, Jie Jin, Lamoureux, Ecosse L.. An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes. Diabetes, vol.62, no.12, 3968-3975.

  31. Pascal, M., Sepulchre, C., Chazan, J.B., Majoie, B.. Evidence for the inhibition of platelet-derived growth factor induced rat smooth muscle cells DNA synthesis by fenofibric acid at the Go/G1 cell cycle level. Life sciences, vol.33, no.10, 925-933.

  32. Nigro, J., Ballinger, M. L., Dilley, R. J., Jennings, G. L. R., Wight, T. N., Little, P. J.. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding. Diabetologia, vol.47, no.12, 2105-2113.

  33. Lee, J.J., Jin, Y.R., Yu, J.Y., Munkhtsetseg, T., Park, E.S., Lim, Y., Kim, T.J., Pyo, M.Y., Hong, J.T., Yoo, H.S., Kim, Y., Yun, Y.P.. Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis, vol.206, no.2, 375-382.

  34. Diep, Quy N., Amiri, Farhad, Touyz, Rhian M., Cohn, Jeffrey S., Endemann, Dierk, Neves, Mario Fritsch, Schiffrin, Ernesto L.. PPARα Activator Effects on Ang II-Induced Vascular Oxidative Stress and Inflammation. Hypertension, vol.40, no.6, 866-871.

  35. Rodriguez-Granillo, Agustina, Rubilar, Bibiana, Rodriguez-Granillo, Gaston, Rodriguez, Alfredo E. Advantages and disadvantages of biodegradable platforms in drug eluting stents.. World journal of cardiology, vol.3, no.3, 84-92.

  36. Fernandez, J., Etxeberria, A., Ugartemendia, J.M., Petisco, S., Sarasua, J.R.. Effects of chain microstructures on mechanical behavior and aging of a poly(L-lactide-co-ε-caprolactone) biomedical thermoplastic-elastomer. Journal of the mechanical behavior of biomedical materials, vol.12, 29-38.

  37. EMJ Thakkar A. S. 114 4 2016 10.33590/emj/10314703 

  38. Bose, Sanjukta, Keller, Stephan S., Alstrøm, Tommy S., Boisen, Anja, Almdal, Kristoffer. Process Optimization of Ultrasonic Spray Coating of Polymer Films. Langmuir : the ACS journal of surfaces and colloids, vol.29, no.23, 6911-6919.

  39. Routledge, Thomas J., Lidzey, David G., Buckley, Alastair R.. Ultrasonic spray coating as an approach for large-area polymer OLEDs: The influence of thin film processing and surface roughness on electrical performance. AIP advances, vol.9, no.1, 015330-.

  40. Shanshan, C., Lili, T., Yingxue, T., Bingchun, Z., Ke, Y.. Study of drug-eluting coating on metal coronary stent. Materials science & engineering. C, Materials for biological applications, vol.33, no.3, 1476-1480.

  41. Mohan, A., Narayanan, S., Balasubramanian, G., Sethuraman, S., Krishnan, U.M.. Dual drug loaded nanoliposomal chemotherapy: A promising strategy for treatment of head and neck squamous cell carcinoma. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V, vol.99, 73-83.

  42. Ramana, L.N., Sharma, S., Sethuraman, S., Ranga, U., Krishnan, U.M.. Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs - Modern Trojan horses to combat HIV. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V, vol.89, 300-311.

  43. Biggs, Kevin B., Balss, Karin M., Maryanoff, Cynthia A.. Pore Networks and Polymer Rearrangement on a Drug-Eluting Stent as Revealed by Correlated Confocal Raman and Atomic Force Microscopy. Langmuir : the ACS journal of surfaces and colloids, vol.28, no.21, 8238-8243.

  44. Jelonek, Katarzyna, Kasperczyk, Janusz, Li, Suming, Dobrzynski, Piotr, Janeczek, Henryk, Jarzabek, Bozena. Novel Poly(L-lactide-co- ε -caprolactone) Matrices Obtained with the Use of Zr[Acac] 4 as Nontoxic Initiator for Long-Term Release of Immunosuppressive Drugs. BioMed research international, vol.2013, 607351-.

  45. 10.2174/138161212803832245 

  46. Mikhalovska, Lyuba, Santin, Matteo, Denyer, Stephen, Lloyd, Andrew, G.Teer, Dennis, Field, Sue, Mikhalovsky, Sergey. Fibrinogen adsorption and platelet adhesion to metal and carbon coatings. Thrombosis and haemostasis, vol.92, no.5, 1032-1039.

  47. Rodriguez, April L., Wojcik, Brandon M., Wrobleski, Shirley K., Myers Jr., Daniel D., Wakefield, Thomas W., Diaz, Jose A.. Statins, inflammation and deep vein thrombosis: a systematic review. Journal of thrombosis and thrombolysis, vol.33, no.4, 371-382.

  48. 10.24170/14-1-1865 

  49. Ali, Ferhana Y., Armstrong, Paul C.J., Dhanji, Al-Rehan A., Tucker, Arthur T., Paul-Clark, Mark J., Mitchell, Jane A., Warner, Timothy D.. Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs. Arteriosclerosis, thrombosis, and vascular biology, vol.29, no.5, 706-711.

  50. Violi, Francesco, Calvieri, Camilla, Ferro, Domenico, Pignatelli, Pasquale. Statins as Antithrombotic Drugs. Circulation, vol.127, no.2, 251-257.

  51. Kadikoylu, Gurhan, Yukselen, Vahit, Yavasoglu, Irfan, Bolaman, Zahit. Hemostatic Effects of Atorvastatin versus Simvastatin. The Annals of pharmacotherapy, vol.37, no.4, 478-484.

  52. Cabanel, Mariana, Brand, Camila, Oliveira-Nunes, Maria Cecilia, Cabral-Piccin, Mariela Pires, Lopes, Marcela Freitas, Brito, Jose Marques, de Oliveira, Felipe Leite, El-Cheikh, Marcia Cury, Carneiro, Katia. Epigenetic Control of Macrophage Shape Transition towards an Atypical Elongated Phenotype by Histone Deacetylase Activity. PloS one, vol.10, no.7, e0132984-.

  53. Liu, Yan-Cun, Zou, Xian-Biao, Chai, Yan-Fen, Yao, Yong-Ming. Macrophage Polarization in Inflammatory Diseases. International journal of biological sciences, vol.10, no.5, 520-529.

  54. Roopmani, Purandhi, Krishnan, Uma Maheswari. Harnessing the pleiotropic effects of atorvastatin-fenofibrate combination for cardiovascular stents. Materials science & engineering. C, Materials for biological applications, vol.92, 875-891.

  55. Hogue, Jean-Charles, Lamarche, Benoît, Tremblay, André J., Bergeron, Jean, Gagné, Claude, Couture, Patrick. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism : clinical and experimental, vol.57, no.3, 380-386.

  56. Tsimihodimos, Vasilis, Kostoula, Angeliki, Kakafika, Anna, Bairaktari, Eleni, Tselepis, Alexandros D., Mikhailidis, Dimitri P., Elisaf, Moses. Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values. Journal of cardiovascular pharmacology and therapeutics, vol.9, no.1, 27-33.

  57. WANG, X.Q., LUO, N.S., CHEN, Z.Q., LIN, Y.Q., GU, M.N., CHEN, Y.X.. Atorvastatin Attenuates TNF-alpha Production via Heme Oxygenase-1 Pathway in LPS-stimulated RAW264.7 Macrophages. Biomedical and environmental sciences : BES = 生物醫學與環境科學 (英文版), vol.27, no.10, 786-793.

  58. Paukkeri, E-L, Leppänen, T, Sareila, O, Vuolteenaho, K, Kankaanranta, H, Moilanen, E. PPARα agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. British journal of pharmacology : BJP, vol.152, no.7, 1081-1091.

  59. Simon, Daniel I.. Inflammation and Vascular Injury : - Basic Discovery to Drug Development -. Circulation journal : official journal of the Japanese Circulation Society, vol.76, no.8, 1811-1818.

  60. Björkhem‐Bergman, Linda, Lindh, Jonatan D., Bergman, Peter. What is a relevant statin concentration in cell experiments claiming pleiotropic effects?. British journal of clinical pharmacology, vol.72, no.1, 164-165.

  61. Krysiak, Robert, Gdula-Dymek, Anna, Bachowski, Ryszard, Okopień, Bogusław. Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes. Diabetes care, vol.33, no.10, 2266-2270.

  62. Tex Heart Inst J. Elieson M. 884 39 2012 

  63. Lai, Chih-Hung, Lin, Yung-Kai, Lee, Wen-Lieng, Chang, Wei-Chun. Coronary Stent Infection Presented as Recurrent Stent Thrombosis. Yonsei medical journal, vol.58, no.2, 458-461.

  64. Ko, Humphrey H.T., Lareu, Ricky R., Dix, Brett R., Hughes, Jeffery D.. Statins: antimicrobial resistance breakers or makers?. PeerJ, vol.5, e3952-.

  65. Muhlestein, J.B., May, H.T., Jensen, J.R., Horne, B.D., Lanman, R.B., Lavasani, F., Wolfert, R.L., Pearson, R.R., Yannicelli, H.D., Anderson, J.L.. The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia. Journal of the American College of Cardiology, vol.48, no.2, 396-401.

  66. Bessler, Hanna, Salman, Hertzel, Bergman, Michael, Straussberg, Rachel, Djaldetti, Meir. In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clinical immunology : the official journal of the Clinical Immunology Society, vol.117, no.1, 73-77.

  67. Won, Tae Wan. Fenofibrate, a peroxisome proliferator-activated receptor α-agonist, blocks lipopolysaccharide-induced inflammatory pathways in mouse liver. Korean journal of hepato-biliary-pancreatic surgery, vol.17, no.3, 89-108.

  68. J. Physiol. Pharmacol. Mason R. P. 65 66 2015 

  69. Feng, Xiaomeng, Gao, Xia, Jia, Yumei, Zhang, Heng, Xu, Yuan, Wang, Guang. PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. Medical science monitor : international medical journal of experimental and clinical research, vol.22, 743-751.

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

관련 콘텐츠

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로